Alphatec Holdings, Inc.

Análisis de la acción Alphatec Holdings, Inc. (ATEC)

$9.440

-0.128 (-1.36%)Al cierre

Loading chart…
High
9.650
Open
9.550
VWAP
9.50
Vol
1.21M
Mkt Cap
1.45B
Low
9.400
Amount
11.48M
EV/EBITDA, TTM
25.16

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.

atecspine.com

AI analysis of Alphatec Holdings, Inc. (ATEC)

buy

Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.

Analyst Ratings (3)

+157.73% upside
Buy
2 Buy
1 Hold
0 Sell
Current: 9.44
Mínimo
20.00
Promedio
24.33
Máximo
28.00

BMO Capital

2026-08-05

Precio objetivo

$12

Outperform

UBS

2026-07-28

Precio objetivo

$15

Buy

Stephens

2026-07-23

Precio objetivo

$15

Overweight

Stifel

2026-07-08

Precio objetivo

$13

Buy

Barclays

2026-05-07

Precio objetivo

$24

Overweight

Métricas de valoración

The current forward P/E ratio for Alphatec Holdings, Inc. (ATEC) is 384.62, compared to its 5-year average forward P/E of 14.23.

Forward P/E

Strongly Overvalued
5Y Average P/E
14.23
Current P/E
384.62
Sobrevalorada
104.98
Infravalorada
-76.52

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
68.17
Current EV/EBITDA
25.16
Sobrevalorada
253.35
Infravalorada
-117.00

Forward P/S

Undervalued
5Y Average P/S
2.68
Current P/S
1.43
Sobrevalorada
3.57
Infravalorada
1.79

Alphio AI Price Scenarios for ATEC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ATEC

$14.87

Precio del escenario

B

Base

Base · 50%ATEC

$14.86

Precio del escenario

B

Bear

Bear · 25%ATEC

$14.36

Precio del escenario

Whales holding ATEC

T

Tremblant Capital Group

+ HoldingATEC

+6.35%

3M Return

T

Tremblant Advisors LP

+ HoldingATEC

+2.37%

3M Return

P

Paradigm Capital Management, Inc.

+ HoldingATEC

-14.65%

3M Return

Cronología de eventos

2026-08-04 (ET)

17:00:00

Company Reaffirms FY2026 Revenue Outlook, Raises EBITDA Guidance to $140 Million

17:00:00

ATEC Reports Q2 Revenue of $214M, Exceeds Expectations

2026-05-05 (ET)

16:50:00

ATEC Reports Q1 Revenue of $192.1M, Below Expectations

16:50:00

Company Expects Total Revenue of $882 Million for Fiscal Year 2026

Noticias

ATEC FAQ — answered by Alphio AI

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Alphatec Holdings Inc is a good buy right now due to its recent revenue growth of 17% year-over-year in Q2 2026, reaching $214 million, and a gross margin improvement to 70.34%. The stock is currently priced at $9.44, significantly below the analyst price target of $15, indicating a potential upside of approximately 58%. However, investors should be cautious of the high forward P/E ratio of 384.62, which suggests that the stock may be overvalued if growth does not continue as expected.

3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis